Glaucoma News

In this Healio Video Perspective, Mohamed Abou Shousha, MD, PhD, FRCS, CEO and founder of Heru Inc., discusses the launch and capabilities of new diagnostic technology platforms, including the Heru re:Vive. He shares study results that were released during Vision Expo West.

Luneau Technology introduced the Visionix VX650, an automated multimodal device for quick, comprehensive visual and ocular exams.

Visual field mean deviation and threshold values found with Heru’s automated visual field testing platform strongly correlated with those of the Zeiss Humphrey Visual Field Analyzer, according to a study released during Vision Expo West.

TearClear has filed an investigational new drug application for its glaucoma drop candidate.

The need for sustained-release glaucoma therapies is clear to anyone caring for patients with the disease.

Patients with ocular hypertension may benefit from cataract surgery, according to findings published in the American Journal of Ophthalmology.

The iStent inject was safe and effective for treating multiple types of primary open-angle glaucoma individually and in conjunction with cataract surgery, according to data published in Journal of Cataract and Refractive Surgery.

Netarsudil maintained IOP control and provided IOP-lowering efficacy when added to other treatments for patients with open-angle glaucoma or ocular hypertension, according to findings published in Current Medical Research and Opinion.

Acutely raising IOP by ophthalmodynamometry increased corneal resistance factor and decreased corneal hysteresis regardless of glaucoma status, according to a study published in Optometry and Vision Science.

Heru announced the commercial release of re:Vive, a portable mixed reality headset designed to provide automated screening and diagnostic exams without the constant presence of a physician.